Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy
- PDF / 1,054,388 Bytes
- 14 Pages / 595.276 x 790.866 pts Page_size
- 29 Downloads / 214 Views
ORIGINAL COMMUNICATION
Hematopoietic stem cell transplantation for chronic inflammatory demyelinating polyradiculoneuropathy Richard K. Burt1 · Roumen Balabanov2 · Jinny Tavee2 · Xiaoqiang Han1 · Robert Sufit2 · Senda Ajroud‑Driss2 · Borko Jovanovic3 · Kathleen Quigley1 · Indira Arnautovic1 · Irene Helenowski3 · Basil Sharrack4 Received: 4 May 2020 / Revised: 15 June 2020 / Accepted: 18 June 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Objective Determine toxicity and efficacy of autologous hematopoietic stem cell transplantation (HSCT) for patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) who are dependent on intravenous immunoglobulins or plasmapheresis. Methods Unselected peripheral blood stem cells were re-infused on day 0 after conditioning with cyclophosphamide 200 mg/ kg/intravenously (IV), rATG (thymoglobulin) 5.5 mg/kg/IV, and rituximab 1000 mg/IV. Results Sixty-six patients underwent HSCT for CIDP. Data on sixty patients with a mean follow-up of 4.5 years (range 2–5 years) were available for analysis. There were no treatment-related deaths, and overall survival was 97%. Post-transplant immune medication-free remission was 80%, 78%, 76% 78%, and 83% at 1, 2, 3, 4, and 5 years. Ambulation without assistance improved from 33% pre-HSCT to 82% 82%, 81%, 86%, and 83% at 1, 2, 3, 4, and 5 years, respectively. Mean right/ left hand grip strength (kg) improved significantly (all p values
Data Loading...
